Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Japan Needs National Efforts to Boost Biosimilar Production: Kameda Chief Pharmacist
The Japanese government should promote the domestic manufacturing of biosimilar products as a national strategy, a prominent pharmacist said on January 19 following Daiichi Sankyo’s decision to discontinue its follow-on biologics for the cancer med Herceptin (trastuzumab). Ryohkan Funakoshi, director…
To read the full story
Related Article
ORGANIZATION
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
- APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
- Flight Cuts, Fuel Costs Tied to Iran Crisis Threaten API Imports: Trader
April 23, 2026
- JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
April 21, 2026
- PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…